Katja M Gist1, David S Cooper2, Julia Wrona1, Sarah Faubel3, Christopher Altmann3, Zhiqian Gao4, Bradley S Marino5, Jeffrey Alten6, Kristal M Hock6, Tomoyuki Mizuno7, Alexander A Vinks7, Melanie S Joy8, Michael F Wempe8, Michael R Bennett9, Stuart L Goldstein2,4,9. 1. Division of Pediatric Cardiology, Department of Pediatrics, The Heart Institute, The University of Colorado, Children's Hospital Colorado, Aurora, Colorado. 2. Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Department of Internal Medicine, Division of Renal Disease and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 4. Heart Institute Research Core, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 5. The Heart Center, Divisions of Cardiology and Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. 6. Department of Pediatrics, Pediatric Cardiac Critical Care Medicine, University of Alabama, Children's of Alabama, Birmingham, Alabama. 7. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 8. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 9. Department of Pediatrics, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
BACKGROUND: Milrinone, an inotropic agent used ubiquitously in children after cardiac surgery, accumulates in acute kidney injury (AKI). We assessed if urinary AKI biomarkers are predictive of an increase in milrinone concentrations in infants after cardiac surgery. METHODS: Multicenter prospective pilot study of infants undergoing cardiac surgery. Urinary AKI biomarkers were measured in the urine at specific time intervals after cardiopulmonary bypass initiation. AKI was defined using the Kidney Disease: Improving Global Outcomes serum creatinine criteria. Serum milrinone concentrations were measured at specific intervals after drug initiation, dose changes, and termination. Excessive milrinone activity was defined as a 20% increase in serum concentration between 6 and 36 hours after initiation. The temporal relationship between urinary AKI biomarker concentrations and a 20% increase in milrinone concentration was assessed. RESULTS: AKI occurred in 31 (33%) of infants. Milrinone clearance was lower in patients with AKI (4.2 versus 5.6 L/h/70 kg; P = 0.02). Excessive milrinone activity was associated with development of serum creatinine-defined AKI [odds ratio (OR) 3.0; 95% confidence interval (CI), 1.21-7.39; P = 0.02]. Both tissue inhibitor metalloproteinase type 2 and insulin-like growth factor-binding protein type 7 (TIMP-2*IGFBP-7) ≥0.78 at 12 hours (OR 2.72; 95% CI, 1.01-7.38; P = 0.04) and kidney injury molecule 1 (KIM-1) ≥529.57 at 24 hours (OR 2.76; 95% CI, 1.06-7.17; P = 0.04) predicted excessive milrinone activity before a diagnosis of AKI. CONCLUSIONS: In this pilot study, urine TIMP-2*IGFBP-7 and KIM-1 were predictive of AKI and excessive milrinone activity. Future studies that include a pharmacodynamics assessment of patient hemodynamics, excessive milrinone activity, and AKI biomarker concentrations may be warranted to integrate this concept into clinical practice.
BACKGROUND:Milrinone, an inotropic agent used ubiquitously in children after cardiac surgery, accumulates in acute kidney injury (AKI). We assessed if urinary AKI biomarkers are predictive of an increase in milrinone concentrations in infants after cardiac surgery. METHODS: Multicenter prospective pilot study of infants undergoing cardiac surgery. Urinary AKI biomarkers were measured in the urine at specific time intervals after cardiopulmonary bypass initiation. AKI was defined using the Kidney Disease: Improving Global Outcomes serum creatinine criteria. Serum milrinone concentrations were measured at specific intervals after drug initiation, dose changes, and termination. Excessive milrinone activity was defined as a 20% increase in serum concentration between 6 and 36 hours after initiation. The temporal relationship between urinary AKI biomarker concentrations and a 20% increase in milrinone concentration was assessed. RESULTS: AKI occurred in 31 (33%) of infants. Milrinone clearance was lower in patients with AKI (4.2 versus 5.6 L/h/70 kg; P = 0.02). Excessive milrinone activity was associated with development of serum creatinine-defined AKI [odds ratio (OR) 3.0; 95% confidence interval (CI), 1.21-7.39; P = 0.02]. Both tissue inhibitor metalloproteinase type 2 and insulin-like growth factor-binding protein type 7 (TIMP-2*IGFBP-7) ≥0.78 at 12 hours (OR 2.72; 95% CI, 1.01-7.38; P = 0.04) and kidney injury molecule 1 (KIM-1) ≥529.57 at 24 hours (OR 2.76; 95% CI, 1.06-7.17; P = 0.04) predicted excessive milrinone activity before a diagnosis of AKI. CONCLUSIONS: In this pilot study, urine TIMP-2*IGFBP-7 and KIM-1 were predictive of AKI and excessive milrinone activity. Future studies that include a pharmacodynamics assessment of patient hemodynamics, excessive milrinone activity, and AKI biomarker concentrations may be warranted to integrate this concept into clinical practice.
Authors: Chirag R Parikh; Prasad Devarajan; Michael Zappitelli; Kyaw Sint; Heather Thiessen-Philbrook; Simon Li; Richard W Kim; Jay L Koyner; Steven G Coca; Charles L Edelstein; Michael G Shlipak; Amit X Garg; Catherine D Krawczeski Journal: J Am Soc Nephrol Date: 2011-08-11 Impact factor: 10.121
Authors: James M Bailey; Timothy M Hoffman; David L Wessel; David P Nelson; Andrew M Atz; Anthony C Chang; Thomas J Kulik; Thomas L Spray; Akbar Akbary; Richard P Miller; Gil Wernovsky Journal: J Pharmacokinet Pharmacodyn Date: 2004-02 Impact factor: 2.745
Authors: Michael Bennett; Catherine L Dent; Qing Ma; Sudha Dastrala; Frank Grenier; Ryan Workman; Hina Syed; Salman Ali; Jonathan Barasch; Prasad Devarajan Journal: Clin J Am Soc Nephrol Date: 2008-03-12 Impact factor: 8.237
Authors: Jef Van den Eynde; Art Schuermans; Jan Y Verbakel; Marc Gewillig; Shelby Kutty; Karel Allegaert; Djalila Mekahli Journal: Eur J Pediatr Date: 2022-01-17 Impact factor: 3.183
Authors: Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2019-06 Impact factor: 6.447
Authors: Katja M Gist; Armin Korst; Stephanie J Nakano; Brian L Stauffer; Anis Karimpour-Fard; Wenru Zhou; Kristen Campbell; Michael F Wempe; Carmen C Sucharov; Shelley D Miyamoto Journal: Cardiol Young Date: 2021-02-03 Impact factor: 1.023